Skip to content

Results of two open-label phase I/II studies of stem cell-derived RPE treatments for retinal degeneration are published in the Lancet

Researchers based at the Jules Stein Eye Institute Retina Division and David Geffen School of Medicine, University of California, Los Angeles, have published the results of embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cell treatments in two retinal degenerative diseases. The phase I/II open label studies were funded by Advanced Cell Technologies, Inc, a Massachusetts based clinical stage biotechnology company focused on regenerative medicine. Results, published online in the The Lancet, indicate that the primary end-points of safety and tolerability were met in addition to a potential positive impact on acuity noted by the investigators.